Rosetta Genomics this week announced that it has signed an agreement making Australia's Genetic Technologies the exclusive distributor of its three miRview microRNA-based diagnostics in Australia, New Zealand, and Singapore.

Under the deal, Genetic Technologies will market Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.